欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日本一区午夜爱爱 | 日本电影亚洲欧美精品素人 | 色翁荡息又大又硬又粗视频 | 嫩草久久99www| 亚洲成人一区二区三区在线观看 | 国产青草视频在线观看 | 欧美大香线蕉线伊人久久 | 久久99精品无毒不卡网站 | 专区在线观看 | 国产精品丝袜久久久久久聚色 | 欧美一区在线日韩 | 亚洲区欧美 | 国产日本欧美一区二区 | 国产男女爽爽爽爽爽爽爽爽 | 影视免费亚洲少妇 | 最新国产在线不卡av | 亚洲电影精品久久 | 日本高清一级婬片a级中文字幕 | 国产亚洲精久久久久久无码 | 一区二区三区视频在线观看 | 亚洲va久久久噜噜噜久久 | 国产精品第二页在线撒放 | 亚洲精品白浆高清久久久 | 久久99精品久久久久婷婷 | 久久只有这里的精 | 性中国妇女熟女xxxx毛多 | 国内在线第一区 | 国产精一品亚洲二区在线播放 | 国产亚洲精品自在久久 | 国产欧美精品区一区二区三区 | 久久成人免费精品二区 | 亚洲性日 | 日韩中文字幕在线播放 | 亚洲精品国男人在线视频 | 日韩在线欧美精品一区二区 | 操天天爽 | 国产女主播勾搭美团在线观看 | 国产揄拍视频在线观看激情五 | 91麻豆免费免费国产在线观看 | 最新精品91探花免费播放 | 亚洲毛片网址在线观看中文字 |